Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice by Willebrords, Joost et al.
1SCIENTIFIC REPORTS | 7: 8268  | DOI:10.1038/s41598-017-08583-w
www.nature.com/scientificreports
Inhibition of connexin 
hemichannels alleviates non-
alcoholic steatohepatitis in mice
Joost Willebrords1, Bruno Cogliati2, Isabel Veloso Alves Pereira2, Tereza Cristina da Silva2, 
Sara Crespo Yanguas  1, Michaël Maes  1, Veronica Mollica Govoni2, Andressa Lima2, Daniele 
Aparecida Felisbino2, Elke Decrock3, Marina Sayuri Nogueira  4, Inar Alves de Castro4, 
Isabelle Leclercq5, Luc Leybaert3, Robim Marcelino Rodrigues1 & Mathieu Vinken1
While gap junctions mediate intercellular communication and support liver homeostasis, connexin 
hemichannels are preferentially opened by pathological stimuli, including inflammation and 
oxidative stress. The latter are essential features of non-alcoholic steatohepatitis. In this study, it 
was investigated whether connexin32 and connexin43 hemichannels play a role in non-alcoholic 
steatohepatitis. Mice were fed a choline-deficient high-fat diet or normal diet for 8 weeks. Thereafter, 
TAT-Gap24 or TAT-Gap19, specific inhibitors of hemichannels composed of connexin32 and connexin43, 
respectively, were administered for 2 weeks. Subsequently, histopathological examination was 
carried out and various indicators of inflammation, liver damage and oxidative stress were tested. In 
addition, whole transcriptome microarray analysis of liver tissue was performed. Channel specificity 
of TAT-Gap24 and TAT-Gap19 was examined in vitro by fluorescence recovery after photobleaching 
analysis and measurement of extracellular release of adenosine triphosphate. TAT-Gap24 and TAT-
Gap19 were shown to be hemichannel-specific in cultured primary hepatocytes. Diet-fed animals 
treated with TAT-Gap24 or TAT-Gap19 displayed decreased amounts of liver lipids and inflammatory 
markers, and augmented levels of superoxide dismutase, which was supported by the microarray 
results. These findings show the involvement of connexin32 and connexin43 hemichannels in non-
alcoholic steatohepatitis and, simultaneously, suggest a role as potential drug targets in non-alcoholic 
steatohepatitis.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, with an estimated 
prevalence of 25% worldwide1. NAFLD represents a spectrum of diseases, ranging from hepatic steatosis to 
non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis and eventually hepatocellular carcinoma2. 
Liver steatosis can be caused by an increased influx of fatty acids through high-fat diet, insulin resistance, drugs 
and genetic factors. As such, steatosis is featured by triglyceride-based lipid droplet accumulation in the cytosol 
of hepatocytes3. Hepatic steatosis may evolve to NASH in response to a number of triggers, such as inflammatory 
cytokines, adipokines, reactive oxygen species and endoplasmatic reticulum stress4.
NASH is driven by a plethora of intracellular signaling cascades, all which underlie the deposition of fat in 
hepatocytes and the induction of an inflammatory reaction5. Knowledge regarding the involvement of intercel-
lular communication in this process is, however, scarce. Direct intercellular communication is predominantly 
mediated by gap junctions, which allow the transfer of small hydrophilic molecules, such as adenosine triphos-
phate (ATP), as well as ions between neighbouring cells. Gap junctions arise from the interaction between 2 
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hemichannels of adjacent cells, which in turn consist of 6 connexin (Cx) proteins. At present, 21 different Cx 
species have been identified, all which are expressed in a cell-specific way. In liver, hepatocytes mainly produce 
Cx32, while the non-parenchymal cell population typically harbours Cx436. However, upon dedifferentiation, as 
seen in several pathological conditions in vivo7 as well as in cultures of primary hepatocytes8, a shift from Cx32 to 
Cx43 expression takes place. In recent years, compelling evidence has shown that Cx hemichannels are not merely 
structural precursors of gap junctions. Indeed, Cx hemichannels can also establish a pathway for communication 
on their own, albeit between the cytosol of an individual cell and its extracellular environment. In contrast to 
gap junctions, Cx hemichannels have a low open probability. They seem to become preferentially activated by 
pathological stimuli, such as decreased extracellular calcium concentration9, mechanical stimulation10, oxidative 
stress11, ischemia/reperfusion insults12 and inflammatory conditions13, 14. We previously reported that Cx32 has a 
protective role in NASH, as evidenced by higher levels of alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), inflammatory cytokines and oxidative stress in Cx32−/− mice15. However, because of genetic abla-
tion of their common building block Cx32, this approach does not allow to distinguish between communication 
mediated by gap junctions and hemichannels. For this reason, the present study was set up, in which NASH mice 
were treated with Gap24 or Gap19 coupled to a transactivator of transcription (TAT) sequence, being peptides 
that act as specific inhibitors of hemichannels consisting of Cx32 and Cx43, respectively, while leaving their full 
gap junction channel counterparts unaffected12. As the targets of both peptides are located within the cell, they 
were indeed linked to a HIV-1 TAT-sequence in order to improve cytosolic uptake16. To our knowledge, this is the 
first study exploring the involvement of Cx hemichannels in NASH.
Results
Effects of TAT-Gap24 and TAT-Gap19 on gap junction activity and connexin hemichannel 
responses. TAT-Gap24 and TAT-Gap19 mimic an amino acid sequence in the intracellular loop region 
of Cx32 and Cx43, respectively. Gap19 was found to bind to the C-terminal area of Cx43, which abolishes the 
interaction between the intracellular loop and the C-terminal area, in turn inhibiting Cx43 hemichannel open-
ing12. A similar mechanism is believed to underlie the actions of TAT-Gap24 on Cx32 hemichannels. In order to 
assess the specificity of TAT-Gap24 and TAT-Gap19 to block Cx hemichannels, but not gap junctions, fluores-
cence recovery after photobleaching (FRAP) analysis was performed in primary rat hepatocyte cultures (n = 4, 
N = 4). Specifically, 24 h after plating, rat hepatocytes were exposed to 20 µM TAT-Gap19, 20 µM TAT-Gap24, 
50 µM carbenoxolone (CBX), a well-known inhibitor of Cx channels17, or vehicle control for 24 h and 48 h. When 
applied at 20 µM, TAT-Gap24 and TAT-Gap19 did not induce cytotoxicity in primary rat hepatocyte cultures 
(Supplementary Fig. 1). CBX significantly reduced fluorescence recovery after 24 h (p < 0.01) and 48 h (p < 0.05) 
compared to vehicle control. This effect was not seen in cell cultures exposed to TAT-Gap24 or TAT-Gap19 
(Fig. 1a). Plateau, half-time and mobile fraction values supported these results (Table 1).
It has been well documented that Cx hemichannels can open upon low extracellular Ca2+ concentrations18. 
Accordingly, a divalent-free buffer was used to trigger their opening. In view of indirectly testing peptide stability, 
TAT-Gap24 and TAT-Gap19 were first incubated at 37 °C for 0 min, 6 days or 20 days in a classic incubator. After 
each time point, extracellular ATP release, a measure of Cx hemichannel activity, was recorded in cultivated 
hepatocytes after 30 min of exposure (n = 3, N = 6). It was found that TAT-Gap24 significantly reduces ATP levels 
after incubation at 37 °C in comparison with vehicle control after 30 min (p < 0.01), 6 days (p < 0.001) and 20 days 
(p < 0.001). The same holds true for TAT-Gap19, which reduced extracellular ATP levels after 30 min (p < 0.05) 
incubation of the peptides (Fig. 1b), thus showing sustained functionality of both peptides.
Effects of TAT-Gap24 and TAT-Gap19 on connexin expression in liver tissue. In mice fed a 
choline-deficient high-fat diet (CHFD) (n = 3), Cx32 mRNA expression was decreased (p < 0.01), while Cx32 
protein expression was elevated (p < 0.05) in comparison with normal diet (ND)-fed animals (n = 3). It has been 
shown that Cx32 mRNA degradation occurs through shortening of the poly(A) tail during inflammation19, while 
Cx32 protein expression is often increased upon inflammation in mice and in liver of hepatitis patients20, 21. Cx26 
and Cx43 expression remained unchanged (Supplementary Figs 2 and 3). In order to verify that administration 
of the Cx hemichannel inhibitors in mice does not affect protein expression of Cx26, Cx32 and Cx43 in liver, 
immunoblot analysis of liver extracts was performed. No effects of the peptides were found on Cx26, Cx32 and 
Cx43 protein expression in TAT-Gap24-treated (n = 3) and TAT-Gap19-treated mice (n = 3) in comparison with 
saline-treated animals (n = 3) (Fig. 2 and Supplementary Fig. 4).
Effects of TAT-Gap24 and TAT-Gap19 on biometric parameters, liver histology and serum 
transaminases. Relative fat weight more than doubled and was significantly higher in CHFD-fed mice 
(n = 14) in comparison with ND-fed counterparts (p < 0.001) (n = 10). This effect was partly diminished in 
TAT-Gap19-treated animals (p < 0.01) (n = 12) in comparison with saline-treated mice (n = 14). No differences 
were seen in TAT-Gap24-treated animals (n = 11) (Fig. 3a). Evaluation of liver biopsy specimens is still considered 
as the gold standard for diagnosing NASH. In particular, histopathological NASH assessment is typically based 
on scoring of steatosis, lobular inflammation and hepatocellular ballooning22. All scores were 0 in the ND-fed 
group (n = 10) and there was an augmentation of steatosis score (p < 0.001), ballooning score (p < 0.001), lobular 
inflammation score (p < 0.001) and NAFLD activity score (NAS) (p < 0.001) in CHFD-fed mice (n = 14) in com-
parison with the ND-fed group (n = 10). The histopathological steatosis score was significantly reduced in both 
TAT-Gap24 (n = 14) (p < 0.05) and TAT-Gap19-treated animals (n = 12) (p < 0.01) in comparison with saline 
mice (n = 12), as clearly seen on hematoxylin-eosin staining (Fig. 3b). In fact, out of 14 mice for TAT-Gap24 and 
12 mice for TAT-Gap19, 5 and 7 animals, respectively, showed less than 5% steatosis. Similar results were obtained 
for lobular inflammation in TAT-Gap24 (n = 14) (p < 0.05) and TAT-Gap19-treated animals (n = 12) (p < 0.01). 
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No significant differences were seen on ballooning. NAS was lower in both treated mouse groups (p < 0.05) 
(Fig. 3b). No effects of the peptides were found on ALT and AST levels (Fig. 4a).
Effects of TAT-Gap24 and TAT-Gap19 on serum and liver lipids. A principal hallmark of NASH 
includes the accumulation of lipid droplets in the cytosol of hepatocytes. These droplets consist of triglycerides 
and are delineated by a phospholipid monolayer. In particular, liver steatosis is triggered by enhanced de novo syn-
thesis of fatty acids or increased influx through diet3. Moreover, cholesterol induces hepatocellular sensitivity to 
inflammatory mediators23. In fact, cholesterol auto-oxidizes to diverse oxysterols under inflammatory and upreg-
ulated oxidative stress conditions. Oxysterols have been suggested to be involved in NASH pathogenesis24. In this 
context, higher amounts of liver triglycerides (p < 0.001) and cholesterol (p < 0.001) were noticed in CHFD-fed 
mice (n = 14). However, after administration of TAT-Gap24, lower levels of triglycerides (p < 0.05) and choles-
terol (p < 0.01) were found in the liver (n = 11) (Fig. 4b). The same holds true for triglycerides (p < 0.05) and 
Figure 1. Effects of TAT-Gap24 and TAT-Gap19 on gap junction activity and connexin hemichannel 
responses. Primary rat hepatocytes were exposed to 50 µM CBX, 20 µM TAT-Gap24, 20 µM TAT-Gap19 or 
vehicle control. (a) Gap junction activity measured through FRAP analysis after 24 h and 48 h (n = 4, N = 4). 
Fluorescence in the bleached cell was expressed as the percentage of recovery relative to the starting level just 
before photobleaching. A similar analysis was performed on cells distant from the bleached area to monitor 
photobleaching outside the targeted region. The recovery values for each experiment were normalized to the 
corresponding vehicle control condition. Pre-bleach (left panel), bleach (middle panel), post-bleach (right 
panel) after 6 min. (b) ATP release 30 min after incubation of TAT-Gap24, TAT-Gap19 or vehicle control for 
0 min, 6 days and 20 days (n = 3, N = 6). Data are expressed as means ± SEM with *p < 0.5, **p < 0.01 and 
***p < 0.001.
Parameter Control Carbenoxolone TAT-Gap24 TAT-Gap19
Exposure time (h) 24 48 24 48 24 48 24 48
Y0 (%) 36.74 54.16 33.23 34.42 48.72 41.82 39.59 41.59
Plateau (%) 76.54 82.36 47.51 48.63 77.30 79.64 69.79 82.54
Tau (s) 67.25 51.53 42.30 46.62 62.63 76.86 61.69 65.60
Half-time (s) 46.62 35.72 29.32 32.32 43.41 53.27 42.76 45.47
Mobile fraction (%) 39.81 28.21 14.28 14.21 28.58 37.82 30.20 40.95
Table 1. Calculations of FRAP curve parameters following a non-linear curve fit of control, carbenoxolone, 
TAT-Gap24 and TAT-Gap19 after 24 h and 48 h of exposure.
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cholesterol (p < 0.001) after TAT-Gap19 administration (n = 11). There were, however, no changes in serum lipid 
concentrations in treated animals (Fig. 4b).
Figure 2. Effects of TAT-Gap24 and TAT-Gap19 on connexin protein expression in liver. After 8 weeks of 
CHFD, an osmotic pump was surgically implanted in the abdominal cavity, which ensured sustained release 
of 1 mg/kg/day TAT-Gap24 (n = 11) or TAT-Gap19 (n = 12) or saline (n = 14) for another 2 weeks, while 
continuing the diet. Immunoblot analysis of Cx26 (21 kDa), Cx32 (27 kDa) and Cx43 (43 kDa) after separation 
and blotting, after which results were normalized to total protein loading. Blot images are cropped. Full-length 
blots are presented in Supplementary Fig. 4. Data are expressed as means ± SEM.
Figure 3. Effects of TAT-Gap24 and TAT-Gap19 on biometric parameters and liver histology in NASH. After 8 
weeks of CHFD, an osmotic pump was surgically implanted in the abdominal cavity, which ensured sustained 
release of 1 mg/kg/day TAT-Gap24 (n = 11) or TAT-Gap19 (n = 12) or saline (n = 14) for another 2 weeks 
while continuing the diet. (a) Body, fat and liver of mice and relative liver and fat weight. (b) Steatosis, lobular 
inflammation, ballooning and NAS score based on hematoxylin-eosin staining of liver tissue of ND group (first 
panel), saline group (second panel), TAT-Gap24 (third panel) and TAT-Gap19 group (fourth panel). Data are 
expressed as means ± SEM with *p < 0.5, **p < 0.01 and ***p < 0.001.
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Effects of TAT-Gap24 and TAT-Gap19 on cytokines. Steatotic hepatocytes can induce cytokine and 
chemokine production in Kupffer cells with subsequent recruitment and activation of inflammatory cells25. 
Bearing this in mind, a number of pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, interferon 
(IFN)-γ and tumor necrosis factor (TNF)-α, and anti-inflammatory cytokines, namely IL-10, which are con-
sidered of relevance for controlling hepatic injury-associated inflammation26, were monitored in this study. 
No detectable levels of cytokines could be found in ND-fed mice (n = 10). Statistically significant lower lev-
els of IL-1β (p < 0.05), IL-6 (p < 0.05) and IFN-γ (p < 0.01) were found upon treatment of NASH mice with 
TAT-Gap24 (n = 11), while levels of TNF-α and IL-10 were unchanged (Fig. 5a). Similar effects were noticed 
in TAT-Gap19-treated NASH mice (n = 12), which showed decreased amounts of IL-1β (p < 0.001) and TNF-α 
(p < 0.001).
Effects of TAT-Gap24 and TAT-Gap19 on oxidative stress. A major contributor to the pathogenesis of 
NASH is oxidative stress, typified by the excessive production of reactive oxygen species. Superoxide dismutase 
(SOD), an enzyme responsible for catalyzing superoxide anions, is usually downregulated in the presence of 
reactive oxygen species, which also holds true in NASH mice in comparison with lean littermates27. This equally 
applies to glutathione reductase (GR), glutathione peroxidase (GPx) and catalase, being anti-oxidant enzymes28. 
In fact, mice and human patients with NASH exhibit decreased glutathione content, SOD and catalase activi-
ties27, 29. Interestingly, higher levels of GPx (p < 0.01) and catalase (p < 0.001) as well as lower amounts of SOD 
(p < 0.01) were seen in the liver of mice fed a CHFD (n = 14) in comparison with ND-fed animals (n = 10). The 
effects of SOD was partially reversed (p < 0.01) in liver of TAT-Gap24-treated (n = 12) and TAT-Gap19-treated 
mice (n = 12) (p < 0.001) (Fig. 5b).
Effects of TAT-Gap24 and TAT-Gap19 on the liver transcriptome. In order to shed more light onto 
the mechanism by which Cx hemichannel inhibition contributes to a decrease in NASH, whole transcriptome 
analysis was performed on isolated RNA of liver tissue of TAT-Gap19-treated (n = 8), TAT-Gap24-treated (n = 6), 
and saline-treated (n = 9) NASH animals, and ND-fed mice. As such, 374 genes were found to be differentially 
expressed in CHFD-fed mice (n = 9) in comparison with ND-fed littermates. Some of the most important path-
ways involved include cholesterol biosynthesis (Hmgcs1, Fdps, Sqle, Nsdhl) cytochrome P450 oxidation (Cyp17a1, 
Cyp51, Cyp7b1, Cyp2f2), and insulin signaling (G6pc, Aldoc, Got1, Gys2), which showed mainly downregulated 
genes and fatty acid β-oxidation (Cd36, Fabp2, Slc27a), and peroxisome proliferator-activated receptor signa-
ling (Cd36, Lpl, Cyp4a14), which exhibited mostly upregulated genes (Supplementary Table 1). Several genes 
encoding proteins involved in lipid transport (Mfsd2a, Cd36), T-cell regulation (Adgre1, Vsig4, Clec7a), gen-
eral inflammatory response (Lilr4b, Ifi27l2b, Cd68, Cd5l, Ly86, Fcer1g, and C1qb), and oxidation (Hmox1, Cybb, 
and Gsta2) were downregulated, while a gene involved in cholesterol catabolism (Cyp7b1) was upregulated in 
the TAT-Gap19-treated group. Moreover, expression of a number of microRNAs linked to tumour suppression 
(Mir15a and Mir101b) was increased (Supplementary Table 2). Differentially expressed genes in the TAT-Gap24 
group have more obscure functions (Supplementary Table 3). To substantiate some of the findings at the tran-
scriptional level, a number of gene changes were verified at the translational level using immunoblot analysis. 
Complying with the microarray data, lower protein levels of cluster of differentiation (CD)36 (p < 0.05), a key 
protein in hepatic uptake of fatty acids30, were detected in liver of TAT-Gap19-treated mice. Similar effects 
Figure 4. Effects of TAT-Gap24 and TAT-Gap19 on serum transaminases and serum and liver lipid content 
in NASH. After 8 weeks of CHFD, an osmotic pump was surgically implanted in the abdominal cavity, which 
ensured sustained release of 1 mg/kg/day TAT-Gap24 (n = 11) or TAT-Gap19 (n = 11) or saline (n = 13) for 
another 2 weeks while continuing the diet. (a) Serum ALT and AST. (b) Serum and liver triglycerides and 
cholesterol. Data are expressed as means ± SEM with *p < 0.05 and ***p < 0.001.
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(p < 0.05) were seen at the protein level for nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, a 
superoxide generating enzyme, encoded by the Cybb gene, which forms reactive oxygen species and that plays a 
role in antigen presentation and the regulation of adaptive immunity31. No differences at the protein level were 
found for lymphocyte antigen (LY)86 (Fig. 6 and Supplementary Fig. 5).
Discussion
At present, 3–5% of people worldwide are affected by NASH, thus constituting a global health problem2. Since 
NASH is closely associated with obesity, insulin resistance and other metabolic features, the prevalence is antici-
pated to steeply increase in the upcoming years32. Therefore, there is an urgent need for drugs to efficiently coun-
teract NASH. In the last decade, it has become clear that Cx hemichannels can act as pathological pores, as they 
are opened upon fatty acid exposure33, inflammation14 and oxidative stress11. In the present study, the potential 
role of Cx32 and Cx43 hemichannels in NASH was investigated. This research relied on the use of TAT-Gap24 
and TAT-Gap19, which reproduce specific amino acid modules in the intracellular loop domain of Cx43 and 
Cx32, respectively. In line with work from other groups using different cell types12, 18, TAT-Gap24 and TAT-Gap19 
were found to inhibit extracellular ATP release, indicative for Cx hemichannel activation, but not gap junctions, 
in cultures of primary rat hepatocytes. Concerning FRAP analysis, the recovery plateaus at 48 h are slightly higher 
than the recovery plateaus at 24 h. In fact, upon 2-step collagenase isolation of hepatocytes from the rat liver, the 
vast array of intercellular contacts becomes abolished, resulting in the loss of normal cytoarchitecture34–36 and gap 
junctions37. After 12 h of cultivation, hepatocytes start to regain their normal morphology, and after about 24 h, 
de novo intercellular contacts reappear34, 36. Thereafter, gap junctional intercellular communication is increased 
at 72 h in comparison with 48 h of cultivation37. This effect probably contributes to the higher recovery plateau at 
48 h of exposure to carbenoxolone, TAT-Gap24 and TAT-Gap19 in comparison with 24 h. In a next set of experi-
ments, TAT-Gap19 and TAT-Gap24 were tested in a mouse model of NASH. Of note, the in vitro results obtained 
in rat hepatocytes are comparable to the in vivo model in mice, as there are only marginal differences between 
both species in Cx32 and Cx43 amino acid sequences38, 39. Importantly, it has been shown in a variety of cell types, 
such as astrocytes, HeLa cells, T cells and CHO cells40, that the TAT sequence can internalize through different 
receptors, including CD2641, lipoprotein receptor-related protein42 and CXC chemokine receptor 443. Gap19 has 
an intracellular target located on the C-terminal tail of Cx43 to which it binds with a Kd of ~2.5 μM12, making it 
Figure 5. Effects of TAT-Gap24 and TAT-Gap19 on inflammatory cytokines and oxidative stress in NASH. 
After 8 weeks of CHFD, an osmotic pump was surgically implanted in the abdominal cavity, which ensured 
sustained release of 1 mg/kg/day TAT-Gap24 (n = 11) or TAT-Gap19 (n = 12) or saline (n = 14) for another 2 
weeks while continuing the diet. (a) Levels of IFN-γ, IL-6, IL-1β, TNF-α and IL-10 in liver tissue and serum. 
(b) Activity of SOD, GR, GPx and catalase in liver tissue. Data are expressed as means ± SEM with *p < 0.05, 
**p < 0.01, and ***p < 0.001.
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possible that the peptide can be trapped and retained intracellularly. Gap24 is believed to act in a similar way on 
Cx3218. Both TAT-Gap24-treated and TAT-Gap19-treated NASH mice exhibited decreased levels of triglycer-
ides, cholesterol, IL-1β as well as higher quantities of SOD in liver tissue. Moreover, TAT-Gap19 also decreased 
levels of ALT and TNF-α, while TAT-Gap24-treated mice presented lower IFN-γ and IL-6 levels. It should be 
stressed, however, that non-specific effects can as such not be fully excluded from this study because of the lack 
of scrambled peptide control. SOD, catalase, GR and GPx activity levels are usually decreased during NASH27, 29, 
as overproduced reactive oxygen species may directly deplete antioxidant molecules and inhibit the activities of 
antioxidant enzymes44. Since catalase, GPx and SOD perform their enzymatic activity in close relationship to each 
other44, decreases in catalase and GPx activity could reflect a compensatory mechanism to the increased activity 
levels of SOD.
To further investigate the mechanistic basis of the effects triggered by pharmacological Cx hemichan-
nel inhibition, whole transcriptome microarray analysis was performed on liver tissue of saline-treated, 
TAT-Gap24-treated, and TAT-Gap19-treated NASH mice. Several genes associated with fatty acid transport, 
inflammation and oxidative stress became differentially expressed upon Cx hemichannel inhibition. Of those 
genes, CD36, an important protein in the transport of fatty acids into cells, such as monocytes/macrophages, 
smooth muscle cells, Kupffer cells and stellate cells, was downregulated both at the RNA and protein level in 
TAT-Gap19-treated NASH animals. CD36 was recently described to be involved in NASH, as its expression is 
elevated in ob/ob mice, db/db mice and mice fed a high-fat diet, and highly correlates with hepatic triglyceride 
content30. Protein levels of NADPH oxidase were also downregulated in TAT-Gap19-treated NASH animals. 
NADPH oxidase was recently reported to have a malicious effect in NASH, since mice deficient in NADPH 
oxidase fed a high-fat diet are protected from developing NASH45. Other oxidative stress markers, such as Gsta2 
and Hmox1, which code for glutathione S-transferase and heme oxygenase, respectively, are often elevated in 
NAFLD46, but were decreased in TAT-Gap19-treated NASH animals. Interestingly, higher Cyp7b1 gene expres-
sion was found in TAT-Gap19-treated NASH animals. CYP7B1 or oxysterol 7α-hydroxylase partially catalyzes 
the conversion of cholesterol to chenodeoxycholic acid, which could explain the reduced liver cholesterol levels 
in TAT-Gap19-treated NASH animals. In human NASH samples, CYP7B1 expression is increased and this is 
believed to be an attempt by the liver to reduce hepatotoxicity during disease progression to NASH47. Other 
negatively affected genes include Adgre148, Cd5l49, and Cd6850, all which are associated with NAFLD pathology. 
In fact, Cd68 is a typical monocyte/macrophage marker51, which could suggest that TAT-Gap19 has an effect on 
the recruitment of monocytes to the liver52. However, it still needs to be determined whether these gene changes 
are a direct or indirect effect of the inhibition of Cx32 and Cx43 hemichannels53. It can not be ruled out that 
TAT-Gap19 also inhibits Cx43 hemichannels in other cell types, such as Kupffer cells or adipocytes. In case of the 
former, this would explain the decrease in levels of inflammatory cytokines, including IL-1β, TNF-β and IL-651. 
Concerning adipocytes, a possible explanation could be presented for the decrease in relative fat weight. The 
same applies to Cx32, which is also expressed in cells of the stomach and intestines54, 55. In fact, involvement of 
the gut microbiome in the pathogenesis of NASH is increasingly accepted, since diet can modulate the gut micro-
biome and the subsequent inflammatory response56. As Cxs are key drivers of inflammation57, it seems plausible 
that Cx32 and/or Cx43 play a role in the liver-gut axis and thus in NASH. While the results of the current study 
show that Cx32 hemichannel inhibition alleviates pathological NASH features, whole-body knock-out of Cx32 
in NASH mice was found to result in higher lipid content, inflammation and oxidative stress15. This could point 
to different roles for Cx32 gap junctions and Cx32 hemichannels in NASH, with the former fulfilling a protec-
tive function and the latter acting as pathological pores. It remains to be elucidated how exactly inhibition of Cx 
hemichannels can cause these effects in experimental NASH. Analysis of The Human Metabolome Database 
Figure 6. Protein expression analysis of liver tissue of TAT-Gap24 and TAT-Gap19-treated NASH animals. 
After 8 weeks of CHFD, an osmotic pump was surgically implanted in the abdominal cavity, which ensured 
sustained release of 1 mg/kg/day TAT-Gap24 (n = 6) or TAT-Gap19 (n = 8) or saline (n = 9) for another 2 weeks 
while continuing the diet. Immunoblot analysis of CD36 (53 kDa), NADPH oxidase (65 kDa) and LY86 (24 kDa) 
after separation and blotting, after which results were normalized to total protein. Blot images are cropped. Full-
length blots are presented in Supplementary Fig. 5. Data are expressed as means ± SEM with *p < 0.05.
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reveals that there are over 35000 biological molecules that could theoretically pass through gap junctions or Cx 
hemichannels58. There has been a large push in the last 20 years to determine at least some of the signaling mol-
ecules, ions and metabolites passing through specific gap junctions and Cx hemichannels59. Out of these signals, 
it is likely that ATP is one of the major players in the working mechanism of inhibition of Cx hemichannels, as it 
is associated with a diverse array of pathological processes, especially through purinergic signaling60. Purinergic 
receptors allow immune cells to recognize ATP released from damaged or stressed host cells. Thus, purinergic 
signaling of immune cells serves as an important function in the recognition of danger signals. Moreover, phago-
cytes recognize ATP that is released by stressed cells as a ‘find-me signal’, which guides phagocytes to inflamma-
tory sites and promotes clearance of damaged and apoptotic cells61.
In summary, inhibition of Cx hemichannels may open perspectives for the establishment of new therapeutic 
strategies for NASH treatment.
Materials and Methods
Animals and treatment. 8-week old male C57BL/6 mice were housed in the animal facility of the 
Department of Pathology, School of Veterinary Medicine and Animal Science of the University of São Paulo-
Brazil. The animals were kept in a room with ventilation, relative humidity, controlled temperature and light/
dark cycle 12:12, and were given water and a CHFD (35% total fat and 54% trans fatty enriched) (Rhoster, 
Brazil) or ND ad libitum. After 8 weeks of diet, an osmotic pump (Alzet, USA) was surgically implanted in the 
abdominal cavity, which ensured sustained release of 1 mg/kg/day TAT-Gap24 or TAT-Gap19 (>90% purity) 
(ThermoFischer, Germany) or saline for another 2 weeks, while continuing the diet. Because of persistent solubil-
ity issues, scrambled peptides have not been routinely included in these experiments. Mice were euthanized after 
10 weeks by isoflurane-induced anaesthesia and exsanguination during sampling. Blood samples were drawn 
into heparinized syringes and centrifuged for 10 min at 4000 × g, and serum was stored at −80 °C. Liver and 
abdominal fat tissues of each animal were weighed, and relative liver and fat weights were calculated. Liver frag-
ments were fixed in 10% phosphate-buffered formalin or snap-frozen in liquid nitrogen with storage at −80 °C. 
This study has been approved by the Committee on Bioethics of the School of Veterinary Medicine and Animal 
Science of the University of São Paulo (Protocol number 9999100314) and all animals received humane care 
according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals”.
Hepatocyte isolation and cultivation. Male outbred Sprague-Dawley rats (Charles River Laboratories, 
Belgium) were kept under controlled environmental conditions with free access to food and water. Hepatocytes 
were isolated by use of a 2-step collagenase perfusion method, including purification by serial differential cen-
trifugation, and cell viability was assessed by trypan blue exclusion35. Viable ( ≥85%) hepatocytes were plated at 
a density of 0.56 × 105 cells per cm2 in William’s medium E (Invitrogen, USA) supplemented with 7 ng/mL gluca-
gon, 292 mg/mL L-glutamine, antibiotics (7.33 IU of sodium benzyl penicillin, 50 μg/mL kanamycin monosulfate, 
10 μg/mL sodium ampicillin, and 50 μg/ml streptomycin sulfate), and 10% fetal bovine serum. After 4 h, 24 h and 
48 h, the cell culture medium was removed and replaced by serum-free medium supplemented with 25 μg/mL 
hydrocortisone sodium hemisuccinate and 0.5 μg/mL insulin. Procedures for the housing of rats, and isolation 
and cultivation of hepatocytes were approved by the Ethical Committee for Animal Experiments of the Vrije 
Universiteit Brussel (Project number 14-210-1) and all animals received humane care according to the criteria 
outlined in the “Guide for the Care and Use of Laboratory Animals”.
Fluorescence recovery after photobleaching. For FRAP analysis 24 h after cell plating, cultured rat 
hepatocytes were exposed to 50 µM CBX, 20 µM TAT-Gap24, 20 µM TAT-Gap19 or vehicle control for 30 min, 
24 h and 48 h. FRAP analysis was performed as previously described37. Fluorescence in the bleached cell was 
expressed as the percentage of recovery relative to the starting level just before photobleaching. A similar analysis 
was performed on cells distant from the bleached area to monitor photobleaching outside the targeted region. 
The recovery values for each experiment were normalized to the corresponding vehicle control condition. 
Additionally, Y0, plateau, tau, half-time and mobile fraction values were calculated following a non-linear curve 
fit.
Measurement of extracellular adenosine triphosphate. Extracellular released ATP was meas-
ured using a commercial luciferin/luciferase assay kit (Sigma, USA) as previously described37. TAT-Gap24 
and TAT-Gap19 were first incubated at 37 °C for 0 min, 6 days or 20 days in a classic incubator (Galaxy 170S, 
New Brunswick, Germany). Primary rat hepatocyte cultures were then exposed to 20 µM TAT-Gap24, 20 µM 
TAT-Gap19, 50 µM CBX or vehicle control for 30 min. These experiments were performed 24 h after isolation of 
the primary hepatocytes.
Histopathological examination. Liver tissue samples were fixed in 10% phosphate-buffered formalin for 
24 h and embedded in paraffin wax. Samples were cut into 5 µm sections and stained with hematoxylin-eosin 
for evaluation of steatosis, hepatocellular ballooning, lobular inflammation and NAS as previously described22. 
The degree of steatosis was graded using the following 4-point scale, namely grade 0, steatosis involving <5% of 
hepatocytes; grade 1, steatosis involving up to 33% of hepatocytes; grade 2, steatosis involving 33–66% of hepato-
cytes; grade 3, steatosis involving >66% of hepatocytes. Lobular inflammation was also graded on a 4-point scale, 
namely grade 0, no foci; grade 1, fewer than 2 foci per ×20 field; grade 2, 2 to 4 foci per ×20 field; grade 3, more 
than 4 foci per ×20 field. Hepatocyte ballooning was graded on a 3-point scale: 0, none; 1, a few balloon cells; 2, 
any/prominent balloon cells. For NAS, features of steatosis, lobular inflammation and hepatocyte ballooning were 
combined with values from 0 to 8.
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Analysis of serum aminotransaminases, serum and liver triglycerides and cholesterol. Liver 
lipids were extracted by means of chloroform/methanol. Specifically, liver tissue was homogenized in 1 mL 2:1 
chloroform/methanol solution and shaken for 1 h in a Thermomixer (Eppendorf, Germany) at 22 °C. Samples 
were centrifuged for 10 min at 5000 × g after which the supernatant was taken. Next, 200 µL distilled water was 
added and samples were centrifuged for 5 min at 8000 × g. The bottom phase was dried overnight at 37 °C. Prior 
analysis, lipids were dissolved in 400 µL butanol (Sigma, USA). ALT, AST, triglycerides and cholesterol were meas-
ured by a chemistry analyser (Labmax 240, Labtest, Brazil). Results were expressed in IU/L for AST and ALT, mg/
dL for serum triglycerides and cholesterol, and µg/mg for liver triglycerides and cholesterol.
Analysis of liver inflammatory cytokines. Liver tissue was homogenized in lysis buffer with protease 
inhibitors (Roche, Germany). Homogenates were centrifuged at 14000 × g for 15 min at 4 °C and protein concen-
trations in supernatants were determined by the Bradford procedure62 using a commercial kit (Bio-Rad, USA) 
with bovine serum albumin as a standard. ELISA kits were used to measure levels of IL-1β, IL-6, IL-10, IFN-γ and 
TNF-α (BD Biosciences, USA) in liver63.
Analysis of liver anti-oxidative enzymes. SOD activity in liver homogenates was determined using a 
microassay as described previously64. The SOD scavenging of superoxide anion radical was calculated by inter-
polation of the percentage of inhibition of the formazan formation using linear regression prepared with SOD 
from bovine erythrocytes (Sigma, USA). Determination of GPx activity was performed using the procedure as 
outlined previously65. Tert-butylhydroperoxide was used as a substrate and the formation of oxidized glutathione 
was monitored spectrophotometrically through nicotinamide adenine dinucleotide phosphate consumption at 
340 nm over 4 min at 37 °C. GPx activity was calculated by linear regression using the percentage of inhibition 
promoted by GPx (Sigma, USA). Determination of GR activity was performed as previously described66. GR 
activity was calculated by linear regression using the percentage of inhibition of nicotinamide adenine dinu-
cleotide phosphate oxidation promoted by GR (Sigma, USA). Catalase activity was determined as previously 
described67. Liver homogenate containing 0.05 µg/µL of protein (20 µL) was added to a microplate with 140 µL 
phosphate-buffered saline (50 mM with 0.1 mM ethylenediamine tetra-acetic acid, pH 7.4) and 40 µL 30 mM 
freshly prepared hydrogen peroxide. The absorbance was continuously monitored over 8 min at 30 °C at 240 nm. 
A standard curve was prepared using catalase enzyme (Sigma, USA). All results were expressed as U/mg protein.
Whole transcriptome analysis. Total RNA was extracted from liver fragments using a GenElute 
Mammalian Total RNA Purification Miniprep Kit (Sigma, USA) according to the manufacturer’s instructions. 
Purity and quantification of the isolated RNA were determined by spectrophotometric analysis using a Nanodrop 
spectrophotometer (Thermo Scientific, USA). RNA integrity was analyzed by microfluidic analysis by means of 
an Agilent 2100 Bioanalyser (Agilent Technologies, USA). As such, 100 ng total RNA per sample was amplified 
with a Genechip 3′ IVT Express Kit, thereby following the manufacturer’s instructions (Affymetrix, Germany). 
Amplified RNA was purified with magnetic beads and 15 mg biotin-amplified RNA was treated with the frag-
mentation reagent. Subsequently, 12.5 µg fragmented amplified RNA was hybridized to Affymetrix Clariom™ 
D mouse arrays and placed in a Genechip Hybridization Oven-645 (Affymetrix, Germany) rotating at 60 rpm at 
45 °C for 16 h. Thereafter, the arrays were washed on a Genechip Fluidics Station-450 (Affymetrix, Germany) and 
stained with an Affymetrix HWS kit. The chips were scanned with an Affymetrix Gene-Chip Scanner-3000-7G 
and quality control matrices were confirmed with Affymetrix GCOS software following the manufacturer’s guide-
lines. Background correction, summarization and normalization of all data were done with Expression Console 
and Affymetrix Transcriptome Analysis Console Software.
Immunoblot analysis. Immunoblot analysis of liver tissue was performed as previously described63. 
Nitrocellulose/PVDF membranes were incubated overnight at 4 °C with primary antibody directed to Cx26 
(1/1000 dilution), Cx32 (1/1000 dilution), Cx43 (1/1000 dilution), CD36 (1/250 dilution), NADPH oxidase 
(1/250 dilution) and LY86 (1/500 dilution) (Sigma, Belgium) followed by incubation for 1 h at room tempera-
ture with appropriate secondary antibody (1/1000 dilution for Cx26, Cx32 and Cx43; 1/500 dilution for CD36, 
NADPH oxidase and LY86) (Dako, Denmark). Densitometric analysis was performed using Image Lab 5.0 soft-
ware (Bio-Rad, USA). For semi-quantification purposes, signals were normalized against total protein, measured 
by Stain-Free gels, and expressed as relative alterations compared to ND-fed animals.
Statistical analysis. The number of biological (n) and technical (N) repeats for each analysis varied and is 
specified in the discussion of the results. All data were expressed as mean ± standard error of mean (SEM). Results 
were statistically processed by 1-way analysis of variance with post hoc Bonferroni correction. All data were pro-
cessed using GraphPad Prism6 software, with probability (p) values of less than 0.05 considered as significant.
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